论文部分内容阅读
霍奇金淋巴瘤(Hodgkin’s lymphoma,HL)在美国约占淋巴瘤总数的11.7%〔1〕,在我国约占8.54%〔2〕,是所有成人肿瘤中预后最好的。随着治疗策略的不断改进,在西方发达国家,HL早期患者治疗后5年总生存率(OS)约90.8%,进展期患者的5年OS亦能达到80%以上〔3-4〕。目前中国还缺乏准确的统计学资料,国内大系列病例报告中,5年OS在80%左右〔5-6〕,基于此,NCCN指南明确指出
Hodgkin’s lymphoma (HL) in the United States accounts for about 11.7% of the total lymphoma 〔1〕, accounting for about 8.54% in China 〔2〕, the prognosis of all adult tumors is the best. With the continuous improvement of treatment strategies, in the western developed countries, the 5-year overall survival rate (OS) after early treatment of HL is about 90.8% and the 5-year OS of advanced patients can reach more than 80% (3-4). At present, China still lacks accurate statistical data. In the large series of domestic case reports, the 5-year OS is about 80% [5-6]. Based on this, the NCCN Guideline clearly states